GlassScriptPhysician profile
Randa Corley
NPI 1144946245
$1,850.50
in general payments reported to CMS, 2019-2025
22 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $993 · 2024: $572 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $255.16 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $251.15 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $231.38 | 2023-2025 | Caplyta |
| Amgen INC. | $199.06 | 2023-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $185.14 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $129.07 | 2023-2024 | |
| Novo Nordisk INC | $73.41 | 2025 | Wegovy, Ozempic |
| Neurocrine Biosciences, INC. | $69.84 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $67.16 | 2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $57.14 | 2023 | Austedo Xr |
| Sumitomo Pharma America, INC. | $52.94 | 2023 | Aptiom |
| Vanda Pharmaceuticals INC. | $45.30 | 2025 | Fanapt |
| Scilex Pharmaceuticals INC. | $41.52 | 2023 | Ztlido |
| Ardelyx, INC. | $34.48 | 2024 | Ibsrela |
| Exact Sciences Corporation | $29.96 | 2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $23.21 | 2023 | Daybue |
| Glaxosmithkline, LLC. | $20.98 | 2024 | Arexvy |
| Dexcom, INC. | $19.07 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $19.00 | 2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.13 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.21 | 2023 | Breztri |
| Xeris Pharmaceuticals, INC. | $14.19 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randa Corley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.